Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Hepatitis C Virus NS3 Helicase Inhibitor Discovery.

Li K, Frankowski KJ, Hanson AM, Ndjomou J, Shanahan MA, Mukherjee S, Kolli R, Shadrick WR, Sweeney NL, Belon CA, Neuenswander B, Ferguson J, Aubé J, Schoenen FJ, Blagg BSJ, Frick DN.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2011 Dec 16 [updated 2013 Mar 14].

2.

Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease.

Lin C, Kwong AD, Perni RB.

Infect Disord Drug Targets. 2006 Mar;6(1):3-16. Review.

PMID:
16787300
3.
4.

Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.

Njoroge FG, Chen KX, Shih NY, Piwinski JJ.

Acc Chem Res. 2008 Jan;41(1):50-9. doi: 10.1021/ar700109k. Review.

PMID:
18193821
5.

The Discovery and Development of Boceprevir: A Novel, First-generation Inhibitor of the Hepatitis C Virus NS3/4A Serine Protease.

Howe AY, Venkatraman S.

J Clin Transl Hepatol. 2013 Sep;1(1):22-32. doi: 10.14218/JCTH.2013.002XX. Epub 2013 Sep 15. Review.

6.

Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.

Venkatraman S.

Trends Pharmacol Sci. 2012 May;33(5):289-94. doi: 10.1016/j.tips.2012.03.012. Epub 2012 Apr 19. Review.

PMID:
22521415

Supplemental Content

Support Center